Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?

Acta Diabetologica

Volumn 46, Issue 3, 2009, Pages 173-181

  Giugliano, Dario ^a   Standl, Eberhard ^b   Vilsbøll, Tina ^c   Betteridge, John ^d   Bonadonna, Riccardo ^e   Campbell, Ian W ^f   Schernthaner, Gerit Holger ^g   Staels, Bart ^h   Trichopoulou, Antonia ⁱ   Farinaro, Eduardo ^j  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e UNIVERSITY OF VERONA   (Italy)

^f UNIVERSITY OF ST ANDREWS   (United Kingdom)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h INSERM   (France)

ⁱ UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^j UNIVERSITY OF NAPLES FEDERICO II   (Italy)

more..

Author keywords

Antidiabetic drugs; Beta cell function; Cardiovascular disease; Diabetes mellitus, type 2; Disease management

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CANNABINOID 1 RECEPTOR ANTAGONIST; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; INCRETIN;

BLOOD GLUCOSE MONITORING; CARDIOPULMONARY FUNCTION; CARDIOVASCULAR DISEASE; DIABETIC HYPERTENSION; DRUG EFFICACY; EPIDEMIC; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; LIVER FUNCTION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION; DIABETES MELLITUS; FEMALE; HYPERGLYCEMIA; HYPERTENSION; MALE;

DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DISEASE OUTBREAKS; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIC AGENTS; INCRETINS; MALE;

EID: 69849098540     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-009-0134-3     Document Type: Review

References (54)

1. International Diabetes Federation (2006) Diabetes atlas, 3rd edn. International Diabetes Federation, Brussels
2. L Rydén E Standl M Bartnik, et al. 2007 Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 28 88 136 17220161 10.1093/eurheartj/ehm124 (Pubitemid 47355991)
3. FB Hu MJ Stampfler SM Haffner CG Solomon WC Willett JE Manson 2002 Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes Diabetes Care 25 1129 1134 12087009 10.2337/diacare.25.7.1129 (Pubitemid 41071162)
4. E Standl H Stiegler 1993 Microalbuminuria in a random cohort of recently diagnosed type 2 (non-insulin-dependent) diabetic patients living in the greater Munich area Diabetologia 36 1017 1020 8243849 10.1007/BF02374493 1:STN:280:DyaK2c%2FmtlartQ%3D%3D
5. EW Gregg P Sorlie R Paulose-Ram, et al. 2004 Prevalence of lower-extremity disease in the US adult population ≥40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey Diabetes Care 27 1591 1597 15220233 10.2337/diacare.27.7.1591 (Pubitemid 38857431)
6. AS MacGregor JF Price CM Hau AJ Lee MN Carson FG Fowkes 1999 Role of systolic blood pressure and plasma triglycerides in diabetic peripheral arterial disease. The Edinburgh Artery Survey Diabetes Care 22 453 458 10097928 10.2337/diacare.22.3.453 1:STN:280:DyaK1M7pvVSjsw%3D%3D
7. M Kallio C Forsblom PH Groop L Groop M Lepäntalo 2003 Development of new peripheral arterial occlusive disease in patients with type 2 diabetes during a mean follow-up of 11 years Diabetes Care 26 1241 1245 12663604 10.2337/diacare.26.4.1241 (Pubitemid 36929279)
8. CE Bird MH Criqui A Fronek JO Denenberg MR Klauber RD Langer 1999 Quantitative and qualitative progression of peripheral arterial disease by non-invasive testing Vasc Med 4 15 21 10355865 10.1177/1358836X9900400103 1:STN:280:DyaK1M3otF2qtA%3D%3D
9. Choose Control Survey Data (2006) Available from http://www.idf.org/home/ index.cfm?node=295. Accessed 23 April 2008
10. TW Gress FJ Nieto E Shahar MR Wofford FL Brancati 2000 Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis risk in communities study N Engl J Med 342 905 912 10738048 10.1056/NEJM200003303421301 1:CAS:528:DC%2BD3cXisFWmt7o%3D (Pubitemid 30177050)
11. LS Geiss DB Rolka MM Engelgau 2002 Elevated blood pressure among U.S. adults with diabetes, 1988-1994 Am J Prev Med 22 42 48 11777678 10.1016/S0749-3797(01)00399-3 (Pubitemid 34037011)
12. J Stamler O Vaccaro JD Neaton D Wentworth 1993 Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 16 434 444 8432214 10.2337/diacare.16.2.434 1:STN:280:DyaK3s7mtFyrtQ%3D%3D
13. P August 2003 Initial treatment of hypertension N Engl J Med 348 610 617 12584370 10.1056/NEJMcp010357 (Pubitemid 36204956)
14. S Bangalore S Parkar E Grossman FH Messerli 2007 A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus Am J Cardiol 100 1254 1262 17920367 10.1016/j.amjcard.2007.05.057 1:CAS:528:DC%2BD2sXhtFCjsLfE (Pubitemid 47498283)
15. Wiysonge CS, Bradley H, Mayosi BM et al (2007) Beta-blockers for hypertension. Cochrane Database Syst Rev Jan 24(1):CD002003
16. WJ Elliott PM Meyer 2007 Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis Lancet 369 201 207 17240286 10.1016/S0140-6736(07)60108-1 1:CAS:528:DC%2BD2sXntlCnsA%3D%3D (Pubitemid 46111014)
17. H Abuissa PG Jones SP Marso JH O'Keefe Jr 2005 Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials J Am Coll Cardiol 46 821 826 16139131 10.1016/j.jacc.2005.05.051 1:CAS:528:DC%2BD2MXpslygs7c%3D (Pubitemid 41224805)
18. R Padwal SR Majumdar JA Johnson J Varney FA McAlister 2005 A systematic review of drug therapy to delay or prevent type 2 diabetes Diabetes Care 28 736 744 15735219 10.2337/diacare.28.3.736 1:CAS:528:DC%2BD2MXivVais7s%3D (Pubitemid 40315342)
19. DREAM Trial Investigators 2006 Effect of ramipril on the incidence of diabetes N Engl J Med 355 1551 1562 10.1056/NEJMoa065061 (Pubitemid 44550032)
20. UK Prospective Diabetes Study Group 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 837 853 10.1016/S0140-6736(98)07019-6 (Pubitemid 28416718)
21. UK Prospective Diabetes Study Group 1998 Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 317 703 713
22. American Diabetes Association 2008 Standards of Medical Care in Diabetes-2008 Diabetes Care 31 S12 S54 10.2337/dc08-S012
23. European Society of Hypertension-European Society of Cardiology Guidelines Committee 2003 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension J Hypertens 21 1011 1053 10.1097/00004872-200306000-00001 (Pubitemid 36667855)
24. DM Nathan JB Buse MB Davidson, et al. 2006 Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 29 1963 1972 16873813 10.2337/dc06-9912 (Pubitemid 44156663)
25. DM Nathan JB Buse MB Davidson, et al. 2008 Management of hyperglycemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: update regarding the thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 31 173 175 18165348 10.2337/dc08-9016
26. P Gæde P Vedel N Larsen GV Jensen HH Parving O Pedersen 2003 Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 383 393 12556541 10.1056/NEJMoa021778 (Pubitemid 36159355)
27. C Stettler S Alleman P Jüni, et al. 2006 Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials Am Heart J 152 27 38 16824829 10.1016/j.ahj.2005.09.015 1:CAS:528:DC%2BD28Xms1Gkt7k%3D (Pubitemid 43974725)
28. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559
29. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572
30. 1c Diabetes Care 26 881 885 12610053 10.2337/diacare.26.3.881 (Pubitemid 36929359)
31. E Standl M Füchtenbusch 2003 The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type 2 diabetes mellitus Diabetologia 46 Suppl 1 M30 M36 12652356 1:CAS:528:DC%2BD3sXit1Khtr4%3D
32. JA Johnson SR Majumdar SH Simpson EL Toth 2002 Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes Diabetes Care 25 2244 2248 12453968 10.2337/diacare.25.12.2244 1:CAS:528:DC%2BD38Xps1Kks7s%3D (Pubitemid 41071035)
33. UK Prospective Diabetes Study Group 1998 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 854 865 10.1016/S0140-6736(98)07037-8 (Pubitemid 28416719)
34. JM Evans SA Ogston A Emslie-Smith AD Morris 2006 Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin Diabetologia 49 930 936 16525843 10.1007/s00125-006-0176-9 1:CAS:528:DC%2BD28XjvFWrt7o%3D
35. SE Kahn SM Haffner MA Heise, et al. 2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2427 2443 17145742 10.1056/NEJMoa066224 1:CAS:528:DC%2BD28Xht12ntrzF (Pubitemid 44903747)
36. KH Kahler M Rajan GG Rhoads MM Safford K Demissie SE Lu LM Pogach 2007 Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration Diabetes Care 30 1689 1693 17440170 10.2337/dc06-2272 1:CAS:528:DC%2BD2sXotlWhsLY%3D (Pubitemid 47036337)
37. AM Lincoff K Wolski SJ Nicholls SE Nissen 2007 Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials JAMA 298 1180 1188 17848652 10.1001/jama.298.10.1180 1:CAS:528:DC%2BD2sXhtVGmtL3J (Pubitemid 47403104)
38. S Singh YK Loke CD Furberg 2007 Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis JAMA 298 1189 1195 17848653 10.1001/jama.298.10.1189 1:CAS:528:DC%2BD2sXhtVGmtL3K (Pubitemid 47403105)
39. M Nauck F Stöckmann R Ebert W Creutzfeldt 1986 Reduced incretin effect in type 2 (non-insulin dependent) diabetes Diabetologia 29 46 52 3514343 10.1007/BF02427280 1:STN:280:DyaL287msFCmuw%3D%3D (Pubitemid 16162741)
40. T Vilsbøll T Krarup S Madsbad JJ Holst 2002 Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients Diabetologica 45 1111 1119 10.1007/s00125-002-0878-6 (Pubitemid 34985287)
41. MA Nauck N Kleine C Orskov JJ Holst B Willms W Creutzfeldt 1993 Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients Diabetologia 36 741 744 8405741 10.1007/BF00401145 1:STN:280:DyaK2c%2FgvF2qtQ%3D%3D (Pubitemid 23218642)
42. CF Deacon MA Nauck M Toft-Nielsen L Pridal B Willms JJ Holst 1995 Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects Diabetes 44 1126 1131 7657039 10.2337/diabetes.44.9.1126 1:CAS:528:DyaK2MXotVGhu7c%3D
43. T Vilsbøll H Agersø T Krarup JJ Holst 2003 Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects J Clin Endocrinol Metab 88 220 224 12519856 10.1210/jc.2002-021053 (Pubitemid 36115169)
44. T Vilsbøll H Agersø T Lauritsen, et al. 2006 The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects Regul Pept 137 168 172 16934887 10.1016/j.regpep.2006.07.007 (Pubitemid 44838981)
45. YE Chen DJ Drucker 1997 Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard J Biol Chem 272 4108 4115 9020121 10.1074/jbc.272.7.4108 1:CAS:528:DyaK2sXht1Oltbw%3D (Pubitemid 27078475)
46. LB Knudsen PF Nielsen PO Huusfeldt, et al. 2000 Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration J Med Chem 43 1664 1669 10794683 10.1021/jm9909645 1:CAS:528:DC%2BD3cXisVKksLg%3D (Pubitemid 30304999)
47. MA Nauck G Meininger D Sheng L Terranella PP Stein Sitagliptin Study 024 Group 2007 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial Diabetes Obes Metab 9 194 205 17300595 10.1111/j.1463-1326.2006.00704.x 1:CAS:528:DC%2BD2sXjs1SrtLw%3D (Pubitemid 46206563)
48. JQ Purnell C Weyer 2003 Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity Treat Endocrinol 2 33 47 15871553 10.2165/00024677-200302010-00004 1:CAS:528: DC%2BD3sXht1eqs74%3D (Pubitemid 37051601)
49. L Farilla A Bulotta B Hirshberg, et al. 2003 Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets Endocrinology 144 5149 5158 12960095 10.1210/en.2003-0323 1:CAS:528:DC%2BD3sXpsV2gt7g%3D (Pubitemid 37476040)
50. LA Nikolaidis S Mankad GG Sokos, et al. 2004 Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 109 962 965 14981009 10.1161/01.CIR.0000120505.91348.58 1:CAS:528:DC%2BD2cXhsFeisbY%3D (Pubitemid 38282847)
51. T Nyström MK Gutniak Q Zhang, et al. 2004 Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease Am J Physiol Endocrinol Metab 287 E1209 E1215 15353407 10.1152/ajpendo.00237.2004 (Pubitemid 39491964)
52. DH Solomon WC Winkelmayer 2007 Cardiovascular risk and thiazolidinediones: déjà vu all over again? JAMA 298 1216 1218 17848659 10.1001/jama.298.10.1216 1:CAS:528:DC%2BD2sXhtVGmtLrN (Pubitemid 47403111)
53. BM Psaty T Lumley 2008 Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs JAMA 299 1474 1476 18364491 10.1001/jama.299.12.1474 1:CAS:528:DC%2BD1cXjvVSnsb0%3D
54. AC Robinson J Burke S Robinson DG Johnston RS Elkeles 1998 The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control Diabetes Care 21 701 705 9589227 10.2337/diacare.21.5.701 1:STN:280:DyaK1c3ltFWiuw%3D%3D (Pubitemid 28487058)